Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472299 · ClinicalTrials.gov registry record · Phase 4
Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT04472299 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 32 participants.
The verdict
NCT04472299, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.
Interventions
- DRUG Ropivacaine 0.2% Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04472299
The ClinicalTrials.gov registry entry for NCT04472299 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropivacaine 0.2% Injectable Solution is the first listed.
NCT04472299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04472299 about?
NCT04472299 is a clinical study titled "Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery". The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.
What is the current status of trial NCT04472299?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2021-04-09. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT04472299?
The interventions under investigation include: Ropivacaine 0.2% Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT04472299?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.